{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:27:53Z","timestamp":1785806873487,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.vaccine.2012.12.067","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T23:12:32Z","timestamp":1357686752000},"page":"1276-1283","source":"Crossref","is-referenced-by-count":29,"title":["Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands"],"prefix":"10.1016","volume":"31","author":[{"given":"Pieter T.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen B.","family":"Pouwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juul M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelko","family":"Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Wilschut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.vaccine.2012.12.067_bib0005","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.vaccine.2006.02.017","article-title":"The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination","volume":"24","author":"de Melker","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2012.12.067_bib0010","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/320169","article-title":"Herpes zoster in older adults","volume":"32","author":"Schmader","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2012.12.067_bib0015","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2012.12.067_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archinte.1982.00340150091017","article-title":"Immune responses to varicella-zoster in the aged","volume":"142","author":"Burke","year":"1982","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.vaccine.2012.12.067_bib0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/fampra\/19.5.471","article-title":"Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database","volume":"19","author":"Opstelten","year":"2002","journal-title":"Fam Pract"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.12.067_bib0030","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1086\/522152","article-title":"The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine","volume":"197","author":"Schmader","year":"2008","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2012.12.067_bib0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/CMR.9.3.361","article-title":"Varicella-zoster virus","volume":"9","author":"Arvin","year":"1996","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2012.12.067_bib0040","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1046\/j.1365-4362.1997.00241.x","article-title":"A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic","volume":"36","author":"Goh","year":"1997","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.vaccine.2012.12.067_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"issue":"6","key":"10.1016\/j.vaccine.2012.12.067_bib0050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","article-title":"Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey","volume":"6","author":"Oster","year":"2005","journal-title":"J Pain"},{"issue":"8913","key":"10.1016\/j.vaccine.2012.12.067_bib0055","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(94)93106-2","article-title":"Proposed classification of herpes zoster pain","volume":"343","author":"Dworkin","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2012.12.067_bib0060","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin J Pain"},{"issue":"8","key":"10.1016\/j.vaccine.2012.12.067_bib0065","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0895-4356(98)00036-5","article-title":"Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years","volume":"51","author":"Bala","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"49","key":"10.1016\/j.vaccine.2012.12.067_bib0070","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2012.12.067_bib0075","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2012.12.067_bib0080","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1086\/514264","article-title":"Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect","volume":"178","author":"Levin","year":"1998","journal-title":"J Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2012.12.067_bib0085","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/522159","article-title":"Shingles Prevention Study Group. Vaccination against herpes zoster and postherpetic neuralgia","volume":"197","author":"Oxman","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0090","series-title":"Zostavax: EPAR - product information","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0195","series-title":"methods and standardized prices for economic evaluations in health care","article-title":"Guidance for costing research","author":"Hakkaart-van Roijen","year":"2010"},{"issue":"15","key":"10.1016\/j.vaccine.2012.12.067_bib0100","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/archinte.1995.00430150071008","article-title":"The incidence of herpes zoster","volume":"155","author":"Donahue","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1478-7547-8-7","article-title":"A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK","volume":"8","author":"Moore","year":"2010","journal-title":"Cost Eff Resour Alloc"},{"issue":"9","key":"10.1016\/j.vaccine.2012.12.067_bib0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annepidem.2005.12.002","article-title":"Gender as an independent risk factor for herpes zoster: a population-based prospective study","volume":"16","author":"Opstelten","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0115","author":"Statistics Netherlands","year":"2011","journal-title":"CBS Statline"},{"issue":"6","key":"10.1016\/j.vaccine.2012.12.067_bib0120","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"J Pain"},{"issue":"7264","key":"10.1016\/j.vaccine.2012.12.067_bib0125","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/bmj.321.7264.794","article-title":"Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up","volume":"321","author":"Helgason","year":"2000","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.vaccine.2012.12.067_bib0130","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/514342","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"44","author":"Rothberg","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2012.12.067_bib0135","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1086\/523011","article-title":"Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia","volume":"45","author":"Brisson","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2012.12.067_bib0140","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/591132","article-title":"Hospitalizations to treat herpes zoster in older adults: causes and validated rates","volume":"47","author":"Jackson","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.12.067_bib0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/fampra\/cmi055","article-title":"Do herpes zoster patients receive antivirals? A Dutch National Survey in General Practice","volume":"22","author":"Opstelten","year":"2005","journal-title":"Fam Pract"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0150","author":"CVZ: Health Care Insurance Board Netherlands","year":"2011","journal-title":"Medicijnkosten"},{"issue":"9","key":"10.1016\/j.vaccine.2012.12.067_bib0155","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.vaccine.2005.09.026","article-title":"The burden of herpes zoster: a prospective population based study","volume":"24","author":"Scott","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2012.12.067_bib0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","article-title":"Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"145","author":"Hornberger","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0165","author":"Centers for Disease Control","year":"2011","journal-title":"CDC Vaccine Price List"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/1472-6963-10-237","article-title":"Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands","volume":"10","author":"van Lier","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"10.1016\/j.vaccine.2012.12.067_bib0175","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","article-title":"Cost effectiveness of herpes zoster vaccine in Canada","volume":"27","author":"Najafzadeh","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2012.12.067_bib0180","doi-asserted-by":"crossref","first-page":"c2509","DOI":"10.1136\/bmj.c2509","article-title":"Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines","volume":"340","author":"Rozenbaum","year":"2010","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2012.12.067_bib0185","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","article-title":"Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales","volume":"27","author":"van Hoek","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.12.067_bib0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpain.2005.01.014","article-title":"The burden of neuropathic pain: results from a cross-sectional survey","volume":"10","author":"McDermott","year":"2006","journal-title":"Eur J Pain"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12018543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12018543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T02:58:57Z","timestamp":1562554737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12018543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0264410X12018543"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.067","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}